These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 31612835)

  • 21. Cost-Effectiveness of Newer Antidiabetic Drugs as Second-Line Treatment for Type 2 Diabetes: A Systematic Review.
    Zhu J; Zhou Y; Li Q; Wang G
    Adv Ther; 2023 Oct; 40(10):4216-4235. PubMed ID: 37515713
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
    Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glucose-Lowering Medications and Cardiovascular Outcomes.
    Shanmugasundaram M; Pineda JRE; Murugapandian S
    Curr Cardiol Rep; 2021 Mar; 23(4):24. PubMed ID: 33655453
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Possible mechanisms of direct cardiovascular impact of GLP-1 agonists and DPP4 inhibitors.
    Bistola V; Lambadiari V; Dimitriadis G; Ioannidis I; Makrilakis K; Tentolouris N; Tsapas A; Parissis J
    Heart Fail Rev; 2018 May; 23(3):377-388. PubMed ID: 29383638
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Changes in SGLT2i and GLP-1RA real-world initiator profiles following cardiovascular outcome trials: A Danish nationwide population-based study.
    Knudsen JS; Baggesen LM; Lajer M; Nurkanovic L; Ustyugova A; Sørensen HT; Thomsen RW
    PLoS One; 2020; 15(3):e0229621. PubMed ID: 32130249
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Network meta-analysis of nine large cardiovascular outcome trials of new antidiabetic drugs.
    Alfayez OM; Al Yami MS; Alshibani M; Fallatah SB; Al Khushaym NM; Alsheikh R; Alkhatib N
    Prim Care Diabetes; 2019 Jun; 13(3):204-211. PubMed ID: 30713085
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure.
    Sinha B; Ghosal S
    Diabetes Res Clin Pract; 2019 Apr; 150():8-16. PubMed ID: 30794833
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiovascular morbidity and mortality in patients with type 2 diabetes using novel antidiabetic medicines as add-on therapy: an observational real-world study.
    Zerovnik S; Kos M; Locatelli I
    BMJ Open; 2021 Sep; 11(9):e051549. PubMed ID: 34518273
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular mechanisms by which GLP-1 RA and DPP-4i induce insulin sensitivity.
    Yaribeygi H; Sathyapalan T; Sahebkar A
    Life Sci; 2019 Oct; 234():116776. PubMed ID: 31425698
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Type 2 Diabetes Medication and Cardiovascular Benefits.
    Shrestha A; Munankarmi R
    S D Med; 2021 Mar; 74(3):132-135. PubMed ID: 34232594
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Advances in type 2 diabetes therapy: a focus on cardiovascular and renal outcomes.
    Libianto R; Davis TM; Ekinci EI
    Med J Aust; 2020 Feb; 212(3):133-139. PubMed ID: 31910303
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiometabolic Effects of a New Class of Antidiabetic Agents.
    Desouza CV; Gupta N; Patel A
    Clin Ther; 2015 Jun; 37(6):1178-94. PubMed ID: 25754876
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review.
    Hong D; Si L; Jiang M; Shao H; Ming WK; Zhao Y; Li Y; Shi L
    Pharmacoeconomics; 2019 Jun; 37(6):777-818. PubMed ID: 30854589
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Diabetes therapy--novel drugs to come (DPP-4 inhibitors, GLP-1 agonists, SGLT-2 inhibitors)].
    Gallwitz B
    MMW Fortschr Med; 2010 May; 152(20):43-4. PubMed ID: 20552881
    [No Abstract]   [Full Text] [Related]  

  • 35. Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes.
    Zhang Z; Chen X; Lu P; Zhang J; Xu Y; He W; Li M; Zhang S; Jia J; Shao S; Xie J; Yang Y; Yu X
    Cardiovasc Diabetol; 2017 Mar; 16(1):31. PubMed ID: 28249585
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DPP-4 Inhibitors, GLP-1 Receptor Agonists, and SGLT-2 Inhibitors for People With Cardiovascular Disease.
    Sonoda K; Saguil A
    Am Fam Physician; 2022 Jul; 106(1):24-25. PubMed ID: 35839371
    [No Abstract]   [Full Text] [Related]  

  • 37. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
    Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
    Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Uptake of new antidiabetic medicines in 11 European countries.
    Mardetko N; Nabergoj Makovec U; Locatelli I; Janez A; Kos M
    BMC Endocr Disord; 2021 Jun; 21(1):127. PubMed ID: 34172020
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control.
    Bae EJ
    Arch Pharm Res; 2016 Aug; 39(8):1114-28. PubMed ID: 27502601
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Navigating the "MACE" in Cardiovascular Outcomes Trials and decoding the relevance of Atherosclerotic Cardiovascular Disease benefits versus Heart Failure benefits.
    Hupfeld C; Mudaliar S
    Diabetes Obes Metab; 2019 Aug; 21(8):1780-1789. PubMed ID: 30957945
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.